Marshall B Wallach , Brian J Alps , A.Peter Roszkowski , L.David Waterbury
{"title":"RS-51324的神经和心血管药理学，一种潜在的抗抑郁药","authors":"Marshall B Wallach , Brian J Alps , A.Peter Roszkowski , L.David Waterbury","doi":"10.1016/0364-7722(81)90098-9","DOIUrl":null,"url":null,"abstract":"<div><p></p><ul><li><span>1.</span><span><p>1. The neuro- and cardiovascular effects of RS-51324 (DL-4(5)-(2,6dichlorophenyl)-2-methoxycarbonyl-amino-4,5 dihydroimidazole) have been explored in animals.</p></span></li><li><span>2.</span><span><p>2. Antidepressant activities of RS-51324 were demonstrated by reserpine antagonism and L-DOPA potentiation.</p></span></li><li><span>3.</span><span><p>3. Norepinephrine uptake was inhibited but MAO activity was not inhibited by RS-51324.</p></span></li><li><span>4.</span><span><p>4. Peripheral vascular responses to serotonin were potentiated although central effects were not demonstrated.</p></span></li><li><span>5.</span><span><p>5. Cardiovascular experiments indicated that RS-51324 lacked anticholinergic effects but had mild antihistaminic activity.</p></span></li><li><span>6.</span><span><p>6. RS-51324 potentiated tyramine-induced pressor responses.</p></span></li><li><span>7.</span><span><p>7. RS-51324 lacks centrally acting skeletal muscle relaxant activity.</p></span></li><li><span>8.</span><span><p>8. The LD<sub>50</sub> of RS-51324 was greater than 2 gm/kg.</p></span></li><li><span>9.</span><span><p>9. RS-51324 appears to be a membrane-pump inhibiting compound with probable antidepressant activity.</p></span></li></ul></div>","PeriodicalId":20801,"journal":{"name":"Progress in neuro-psychopharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1981-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/0364-7722(81)90098-9","citationCount":"3","resultStr":"{\"title\":\"The neuro- and cardiovascular pharmacology of RS-51324, a potential antidepressant\",\"authors\":\"Marshall B Wallach , Brian J Alps , A.Peter Roszkowski , L.David Waterbury\",\"doi\":\"10.1016/0364-7722(81)90098-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p></p><ul><li><span>1.</span><span><p>1. The neuro- and cardiovascular effects of RS-51324 (DL-4(5)-(2,6dichlorophenyl)-2-methoxycarbonyl-amino-4,5 dihydroimidazole) have been explored in animals.</p></span></li><li><span>2.</span><span><p>2. Antidepressant activities of RS-51324 were demonstrated by reserpine antagonism and L-DOPA potentiation.</p></span></li><li><span>3.</span><span><p>3. Norepinephrine uptake was inhibited but MAO activity was not inhibited by RS-51324.</p></span></li><li><span>4.</span><span><p>4. Peripheral vascular responses to serotonin were potentiated although central effects were not demonstrated.</p></span></li><li><span>5.</span><span><p>5. Cardiovascular experiments indicated that RS-51324 lacked anticholinergic effects but had mild antihistaminic activity.</p></span></li><li><span>6.</span><span><p>6. RS-51324 potentiated tyramine-induced pressor responses.</p></span></li><li><span>7.</span><span><p>7. RS-51324 lacks centrally acting skeletal muscle relaxant activity.</p></span></li><li><span>8.</span><span><p>8. The LD<sub>50</sub> of RS-51324 was greater than 2 gm/kg.</p></span></li><li><span>9.</span><span><p>9. RS-51324 appears to be a membrane-pump inhibiting compound with probable antidepressant activity.</p></span></li></ul></div>\",\"PeriodicalId\":20801,\"journal\":{\"name\":\"Progress in neuro-psychopharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1981-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/0364-7722(81)90098-9\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in neuro-psychopharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/0364772281900989\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in neuro-psychopharmacology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/0364772281900989","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The neuro- and cardiovascular pharmacology of RS-51324, a potential antidepressant
1.
1. The neuro- and cardiovascular effects of RS-51324 (DL-4(5)-(2,6dichlorophenyl)-2-methoxycarbonyl-amino-4,5 dihydroimidazole) have been explored in animals.
2.
2. Antidepressant activities of RS-51324 were demonstrated by reserpine antagonism and L-DOPA potentiation.
3.
3. Norepinephrine uptake was inhibited but MAO activity was not inhibited by RS-51324.
4.
4. Peripheral vascular responses to serotonin were potentiated although central effects were not demonstrated.
5.
5. Cardiovascular experiments indicated that RS-51324 lacked anticholinergic effects but had mild antihistaminic activity.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
